Biotechnology company Oxford Biodynamics (OBD:AIM) has seen its shares go up three-fold in the last month driven by positive news flow.The company, which is developing precision medical tests based on its proprietary EpiSwitch3D genomics platform, announced earlier than expected validation of its prostate screening test on 26 September.

The test is groundbreaking in that it has proven to be 94% accurate in predicting the presence or absence of prostate cancer compared with 55% accuracy from current screening methods used by the NHS.

Increased accuracy of the test, which will be run alongside a standard test, significantly removes false positives and the need for unnecessary referrals and invasive biopsies.

Further exciting news came on 18 October when Oxford Biodynamics announced a strategic partnership with Bupa, the UK’s leading health insurer, to give patients access to EpiSwitch Cirt (Checkpoint inhibitor Response Test).

It is a first-of-its-kind blood test that accurately predicts an individual cancer patient’s therapeutic response to treatment and thereby identifies those most likely to benefit from this class of therapy.

‹ Previous2023-10-26Next ›